This body of evidence indicates that OS-MET-R-092 may represent a reliable preclinical model that could help elucidate the molecular mechanisms underlying the development of osteosarcoma bone metastases and guide the identification of innovative therapeutic strategies for metastatic OS patients. Here, MET is linked to osteosarcoma.